Mission Statement:

To improve the care and outcomes of kidney disease
patients worldwide through promoting coordination,
collaboration and integration of initiatives to develop
and implement clinical practice guidelines.

Home

Guidelines for Mineral and Bone Disorder

Guideline Organization

Sub-topic

CARI-Australia

Biochemical and Haematological Targets
(2006)

 

Vitamin D, Calcimimetics and Phosphate Binders (2006)

Biochemical and Haematological Targets:

 

 

Vitamin D, Calcimimetics and Phosphate Binders:

CSN-Canada
Chapter 3: Mineral Metabolism
(2006)

Management of Serum Phosphate, Serum Calcium and Parathyroid Hormone (Pg 11of 27)

EBPG-Europe

 

KDOQI-US

Bone Metabolism and Disease in Chronic Kidney Disease (2003)

Mineral and Bone Disorder

The Overall Approach to the Management of Bone Metabolism and Disease in CKD Patients

Bone Metabolism and Disease in Children With CKD 2005

Bone Metabolism and Disease in Children With CKD

UK-Renal Association

Module B:
Complication of CKD
(2007)

Management of metabolic bone disease (C-MBD)

  • Serum calcium in patients with Chronic Kidney Disease
  • Serum calcium in Dialysis Patients
  • Serum phosphate in patients with CKD stages 3 and 4
  • Serum phosphate in dialysis patients
  • Serum calcium x phosphate product
  • Measurement of Serum Parathyroid Hormone in CKD
  • Desired outcome range for Serum Parathyroid Hormone in CKD
  • Desired outcome range for Serum Parathyroid Hormone in Dialysis Patients
  • Vitamin D in CKD and Dialysis